Expansion of the genetic and phenotypic spectrum of hereditary spastic paraplegia caused by ABHD16A gene variants: an integrated analysis based on novel variants and literature review

作者：Manling He, Qiang Zhang, Shaoke Chen, Chuan Li, Bobo Xie, Qingxiu Zhao, Yiyun Huang, Xin Fan · 发表于：Frontiers in Pediatrics · 年份：2026 · DOI：10.3389/fped.2025.1724515 · 被引用次数：1 · 研究领域：Hereditary Neurological Disorders、Botulinum Toxin and Related Neurological Disorders、Neurological diseases and metabolism

Background Hereditary spastic paraplegia (HSP) is a clinically and genetically heterogeneous neurodegenerative disorder. Biallelic pathogenic variants in ABHD16A have recently been linked to a neurodevelopmental phenotype featuring early-onset spasticity and global developmental delay. Objective To further define the clinical and genetic spectrum of ABHD16A -associated disease through the characterization of a novel pediatric case and an updated literature review. Methods We evaluated a child presenting with global developmental delay and progressive spastic paraplegia. Whole-exome sequencing (WES) was performed, and candidate variants were validated by Sanger sequencing. Clinical features were documented prospectively, and a systematic review of published cases was conducted to assess phenotypic patterns and genotype–phenotype relationships. Results Consistent with prior reports, the core features of ABHD16A -related disease include global developmental delay, intellectual disability, and spastic paraplegia, often with early onset. In our patient, tandem mass spectrometry revealed elevated long-chain acylcarnitines (C16, C18:1, C18:2)—a metabolic abnormality not previously described in this condition. WES identified two novel compound heterozygous frameshift variants in ABHD16A : c.119delA (p.His40Leufs49) and c.559_562del (p.Pro187Cysfs29), both confirmed by Sanger sequencing and classified as pathogenic (ACMG criteria: PVS1, PM2, PM3, PP1). Our literature review identified...